Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
NEW YORK, March 17, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aratana Therapeutics, Inc securities (NASDAQ:PETX) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”) of the important April 7, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Aratana investors under the federal securities laws.
To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) consequently, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (4) as a result, Aratana’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1049.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
